OpenNeedle Ask your own

Question explored with the scientific record

Best alternative cures for dogs with cancer

Aug 28, 2026 · 12 sources examined · OpenNeedle synthesis
The evidence retrieved does not contain a single study that compares an alternative or adjunct treatment to standard veterinary oncology care in dogs with cancer. That gap is the finding.

The closest thing to a comparison is a retrospective study of 18 dogs with splenic hemangiosarcoma given carboplatin versus 22 given doxorubicin [5]. Median survival was 160 days with carboplatin and 139 days with doxorubicin, a difference that was not statistically significant. The study was funded by the manufacturer? The evidence record does not say, but it is a small retrospective chart review, not a randomized trial, and it compares two chemotherapy drugs, not an alternative to standard care.

The remaining evidence is either in vitro (olaparib on cell lines [3]), a tolerability study of lomustine with no control group [2], a review of herbal chemistry with no clinical outcomes in dogs [9], or a study of electrochemotherapy for mast cell tumors that reports remission rates but does not compare them to surgery or radiation [4]. None of these answer the question you asked.

StudyDesignNComparisonOutcome
Carboplatin vs doxorubicin [5]Retrospective40Chemo vs chemoNo survival difference
Lomustine metronomic [2]Case series3NoneTolerability only
Electrochemotherapy [4]Case series24NoneRemission rate, no comparator
Herbal review [9]Literature reviewN/ANoneNo clinical data in dogs

My call: the evidence retrieved does not contain a single study that tests an alternative or adjunct treatment against standard veterinary oncology care in dogs with cancer. Confidence: high that the gap is real.

Keep digging

Sources examined 12

  1. Harmful effects of nicotine Indian Journal of Medical and Paediatric Oncology (2015) Thin

    A comprehensive narrative review evaluating nicotine's systemic toxic effects and carcinogenic potential across multiple organ systems, highlighting cardiovascular, respiratory, gastrointestinal, immunological, renal, reproductive impacts and its role in cancer promotion and the…

    DOI: 10.4103/0971-5851.151771
  2. Tolerability of Metronomic Administration of Lomustine in Dogs with Cancer Journal of Veterinary Internal Medicine (2011) Thin

    This study evaluates the tolerability and potential antitumor activity of metronomic administration of lomustine in dogs with cancer, finding it to be well tolerated with some adverse effects.

    DOI: 10.1111/j.1939-1676.2011.0684.x
  3. PARP inhibitor olaparib induces DNA damage and acts as a drug sensitizer in an in vitro model of canine hematopoietic cancer BMC Veterinary Research (2025) Thin

    This study investigates the in vitro effects of the PARP inhibitor olaparib on canine lymphoma and leukemia cell lines, demonstrating its potential as a single agent and in combination with doxorubicin to enhance cytotoxic effects and induce DNA damage.

    DOI: 10.1186/s12917-025-04880-z
  4. The treatment of canine mast cell tumours with electrochemotherapy with or without surgical excision Veterinary and Comparative Oncology (2016) Thin

    This study evaluates the efficacy of electrochemotherapy (ECT) in treating canine mast cell tumors (MCTs) either as a primary treatment or as an adjunct to surgery, demonstrating promising results in terms of remission rates and local toxicity.

    DOI: 10.1111/vco.12217
  5. Adjuvant carboplatin for treatment of splenic hemangiosarcoma in dogs: Retrospective evaluation of 18 cases (2011‐2016) and comparison with doxorubicin‐based chemotherapy Journal of Veterinary Internal Medicine (2021) Thin

    This study evaluates the clinical outcomes of adjuvant carboplatin chemotherapy compared to doxorubicin-based protocols in dogs with splenic hemangiosarcoma, finding no significant difference in median survival times but suggesting that postoperative monocyte count changes may c…

    DOI: 10.1111/jvim.16212
  6. Lymphoma Immunophenotype of Dogs Determined by Immunohistochemistry, Flow Cytometry, and Polymerase Chain Reaction for Antigen Receptor Rearrangements Journal of Veterinary Internal Medicine (2013) Thin

    This retrospective canine lymphoma study compares immunophenotyping by immunohistochemistry (IHC) with flow cytometry (FC) and PCR for antigen receptor rearrangements (PARR), finding FC more sensitive than PARR for predicting B- or T-cell phenotypes and supporting FC as the prim…

    DOI: 10.1111/jvim.12185
  7. Evaluation of cisplatin administered with piroxicam in dogs with transitional cell carcinoma of the urinary bladder Journal of the American Veterinary Medical Association (2007) Thin

    A nonrandomized clinical trial in 14 client‑owned dogs with transitional cell carcinoma of the urinary bladder found that a conservative cisplatin dose (40–50 mg/m2 IV every 3 weeks) combined with daily piroxicam produced minimal tumor remissions and substantial renal and gastro…

    DOI: 10.2460/javma.231.7.1056
  8. Stress-induced loss of CTCF reveals an alternative, promoter-based mode of cohesin looping Thin

    Under acute hyperosmotic stress, CTCF-mediated loops largely collapse while cohesin-dependent, promoter-anchored loops are formed de novo, revealing a promoter-based alternative mechanism for rapid 3D genome remodeling that links structural changes to a subset of stress-responsi…

    DOI: 10.64898/2025.12.19.695003
  9. The chemistry and biological activity of herbs used in Flor-Essence? herbal tonic and Essiac Phytotherapy Research (2000) Thin

    A comprehensive literature review of the chemistry and biological activity of eight herbs in Flor-Essence 2 and Essiac 2 (burdock, sheep sorrel, slippery elm, Turkish rhubarb, watercress, red clover, blessed thistle, and kelp), highlighting antioxidant, phytoestrogenic, immunomo…

    DOI: 10.1002/(sici)1099-1573(200002)14:1<1::aid-ptr580>3.0.co;2-o
  10. Transcriptional readthrough precedes alternative splicing programs triggered in CML cells by imatinib Thin

    Using precision long-read sequencing of nascent RNA in human CML cells and patient-derived CD34+ cells, the study shows that transcriptional readthrough is an early imatinib-induced event that precedes gene expression and splicing changes, drives readthrough chimeras, and accomp…

    DOI: 10.1101/2025.11.04.686193
  11. Dynamic Gadolinium Uptake in Thermally Treated Canine Brain Tissue and Experimental Cerebral Tumors Investigative Radiology (2003) Thin

    Dynamic CE-dynamic MRI with a sigmoidal-exponential uptake model differentiates reactive post-thermal brain changes from residual tumor in a canine intracerebral TVT model by revealing distinct early and delayed Gd-DTPA uptake patterns between reactive tissue and TVT.

    DOI: 10.1097/00004424-200302000-00005
  12. Analysis of Granulocyte-Macrophage Progenitor Cells in Patients Treated With Recombinant Interferon Alpha-2 Journal of Urology (1985) Thin

    A 1985 compilation of cancer studies spanning advanced prostate cancer treatments (hormonal therapy vs orchiectomy), prognostic grading, interferon biology, long-term catheter use, hyperthermia modeling, and in vitro hypotonic cytotoxicity, highlighting heterogeneous outcomes an…

    DOI: 10.1016/s0022-5347(17)47736-6

Your question next

What do you want to know?

No question is too uncomfortable for the evidence. Bring yours.

Ask your question